HRP20000094A2 - Methods for lowering platelet counts - Google Patents

Methods for lowering platelet counts Download PDF

Info

Publication number
HRP20000094A2
HRP20000094A2 HR20000094A HRP20000094A HRP20000094A2 HR P20000094 A2 HRP20000094 A2 HR P20000094A2 HR 20000094 A HR20000094 A HR 20000094A HR P20000094 A HRP20000094 A HR P20000094A HR P20000094 A2 HRP20000094 A2 HR P20000094A2
Authority
HR
Croatia
Prior art keywords
platelets
compound
formula
compounds
patients
Prior art date
Application number
HR20000094A
Other languages
English (en)
Croatian (hr)
Inventor
Mark Chandrakant Lakshmanan
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of HRP20000094A2 publication Critical patent/HRP20000094A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HR20000094A 1997-08-21 1998-08-17 Methods for lowering platelet counts HRP20000094A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5620397P 1997-08-21 1997-08-21
PCT/US1998/017018 WO1999008525A1 (fr) 1997-08-21 1998-08-17 Procedes permettant d'abaisser la numeration plaquettaire

Publications (1)

Publication Number Publication Date
HRP20000094A2 true HRP20000094A2 (en) 2000-08-31

Family

ID=22002873

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20000094A HRP20000094A2 (en) 1997-08-21 1998-08-17 Methods for lowering platelet counts

Country Status (22)

Country Link
US (1) US6103740A (fr)
EP (1) EP0904783B1 (fr)
JP (1) JP2001515015A (fr)
KR (1) KR20010023075A (fr)
CN (1) CN1275886A (fr)
AT (1) ATE220905T1 (fr)
AU (1) AU741882B2 (fr)
BR (1) BR9811962A (fr)
CA (1) CA2301806A1 (fr)
DE (1) DE69806705T2 (fr)
DK (1) DK0904783T3 (fr)
EA (1) EA001582B1 (fr)
ES (1) ES2181132T3 (fr)
HR (1) HRP20000094A2 (fr)
HU (1) HUP0002715A3 (fr)
IL (1) IL134551A0 (fr)
NO (1) NO20000750L (fr)
NZ (1) NZ502842A (fr)
PL (1) PL338700A1 (fr)
PT (1) PT904783E (fr)
TR (1) TR200000453T2 (fr)
WO (1) WO1999008525A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624800D0 (en) * 1996-11-29 1997-01-15 Lilly Co Eli Methods of preventing breast cancer
US6353003B1 (en) 1998-06-17 2002-03-05 Eli Lilly And Company Method for reducing levels of homocysteine and C-reactive protein
US6585995B1 (en) * 1999-09-21 2003-07-01 Hanson Stephen R Methods and compositions for treating platelet-related disorders
US20090092693A1 (en) * 2007-10-05 2009-04-09 Mady Attila Platelet manipulation to prevent and treat endovascular disease and its sequelae, to prevent and treat arrhythmias and to prevent malignancy
US8021854B2 (en) * 2007-10-05 2011-09-20 Attila Mady Method of treating vascular disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4447620A (en) * 1982-06-08 1984-05-08 The Upjohn Company Imidazolyl-substituted benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US4847276A (en) * 1988-09-06 1989-07-11 Merrell Dow Pharmaceuticals Inc. Treatment of thromobocytosis with 5-(4-chlorophenyl)-2,4-diemthyl-3H-1,2,4-triazole-3-thione
JPH0517357A (ja) * 1991-07-05 1993-01-26 Nissan Chem Ind Ltd 血小板減少療法剤
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5424334A (en) * 1991-12-19 1995-06-13 G. D. Searle & Co. Peptide mimetic compounds useful as platelet aggregation inhibitors
US5482949A (en) * 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
US5445941A (en) * 1993-06-21 1995-08-29 Eli Lilly And Company Method for screening anti-osteoporosis agents
US5391557A (en) * 1993-10-15 1995-02-21 Eli Lilly And Company Methods for the treatment of peri-menopausal syndrome
US5441965A (en) * 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
US5476862A (en) * 1993-12-21 1995-12-19 Eli Lilly And Company Methods of increasing thrombomodulin expression
US6025373A (en) * 1997-04-22 2000-02-15 Eli Lilly And Company Methods for reducing fibrinogen

Also Published As

Publication number Publication date
NO20000750L (no) 2000-04-13
DE69806705T2 (de) 2003-03-20
HUP0002715A2 (hu) 2001-06-28
BR9811962A (pt) 2000-08-15
EP0904783B1 (fr) 2002-07-24
ES2181132T3 (es) 2003-02-16
AU741882B2 (en) 2001-12-13
EA200000243A1 (ru) 2000-10-30
US6103740A (en) 2000-08-15
ATE220905T1 (de) 2002-08-15
IL134551A0 (en) 2001-04-30
CN1275886A (zh) 2000-12-06
NZ502842A (en) 2001-11-30
PL338700A1 (en) 2000-11-20
WO1999008525A1 (fr) 1999-02-25
EP0904783A1 (fr) 1999-03-31
HUP0002715A3 (en) 2002-12-28
KR20010023075A (ko) 2001-03-26
DE69806705D1 (de) 2002-08-29
DK0904783T3 (da) 2002-09-02
TR200000453T2 (tr) 2000-08-21
CA2301806A1 (fr) 1999-02-25
NO20000750D0 (no) 2000-02-15
JP2001515015A (ja) 2001-09-18
EA001582B1 (ru) 2001-06-25
PT904783E (pt) 2002-10-31
AU8830698A (en) 1999-03-08

Similar Documents

Publication Publication Date Title
US5494920A (en) Methods of inhibiting viral replication
CZ322094A3 (en) Pharmaceutical preparation for inhibiting alzheimer's disease
CA2149092A1 (fr) Methodes permettant d'inhiber la proliferation des cellules des muscles lisses et la restenose de l'aorte au moyen de derives du 1,1,2-triphenylbut-1-ene
AU692490B2 (en) Methods of inhibiting dysfunctional uterine bleeding
AU677701B2 (en) Methods for inhibiting angiogenisis and angiogenic diseases
CZ253794A3 (en) Pharmaceutical preparation for inhibiting endometriosis
KR20030065558A (ko) 아스피린을 함유하는 의약 조성물
HUT71476A (en) Pharmaceutical compositions for inhibition of ldl oxidation and atherosclerosis containing 2-phenyl-3-aroyl-benzothiophene derivatives and process for their preparation
HUT71477A (en) Pharmaceutical compositions for increasing libido in post-menopausal women containing 2-phenyl-3-aroil-benzothiophene derivatives and process for their preparation
HRP20000094A2 (en) Methods for lowering platelet counts
CZ52097A3 (en) Pharmaceutical preparation for inhibiting degeneration of bone prosthesis
EA001911B1 (ru) Способы увеличения продуцирования окиси азота
MXPA00001734A (en) Methods for lowering platelet counts
JPH101479A (ja) 複素環で置換されたベンゾチオフェン化合物及び該化合物を含有する組成物
CZ51997A3 (en) Pharmaceutical preparation for facilitating bone healing or repair of fractures
US5719190A (en) Inhibition of myeloperoxidase activity
US5985932A (en) Inhibition of autoimmune diseases
CZ2000618A3 (cs) Způsob snižování počtu krevních destiček
CZ200085A3 (cs) Léčivo proti srdečním poruchám a farmaceutický prostředek s obsahem SSRI

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODBI Application refused